Search Case Studies
UCL research over the last 30 years has developed new treatments for Hodgkin lymphoma and has improved outcomes for patients who do not respond to conventional therapy.
Research has led to advances in the diagnosis of amyloidosis and clinical characterisation of many new subtypes that has led to new standards of clinical care, improved diagnosis, improved outcomes, and major investment by the NHS.
Using evidence of black and minority ethnic underperformance to improve transparency, fairness and standards in medical examinations
UCL research highlighting medical examination underperformance among UK black and minority ethnic medical students and doctors has informed the development of new or amended guidelines, and changed how international examinations are run.
Professor Sir Mark Pepys and his team in the UCL Wolfson Drug Discovery Unit have invented new chemical entities for treatment of amyloidosis, Alzheimer’s disease, and other conditions.
As a result of research on acid-sensing ion channels (ASICs) in pain regulation, ASIC-related therapies for a wide variety of conditions are now in clinical trials.
Research conducted at UCL/UCLH over the last 20 years has enabled the identification of adults with acute leukaemia who are most likely to benefit from stem cell transplantation.